Esmozole DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the effective management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Esomeprazole, a proton pump inhibitor (PPI), acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting mucosal healing. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, providing symptomatic relief from nausea, vomiting, and bloating associated with delayed gastric emptying and reflux. The dual action of Esmozole DSR Capsule addresses both acid suppression and motility enhancement, offering comprehensive symptom control in patients with erosive esophagitis, non-ulcer dyspepsia, and functional dyspepsia. It is generally well-tolerated; however, caution is advised in patients with cardiac arrhythmias or electrolyte imbalances due to Domperidone’s potential to prolong the QT interval. Esmozole DSR should be administered under medical supervision, with dosage adjustments based on clinical response and patient tolerance. This combination therapy improves patient compliance by reducing pill burden while effectively managing complex gastrointestinal symptoms.